Roivant drug Mosliciguat meets Phase 2 goal; ROIV shares jump premarket
Roivant’s experimental lung disease drug Mosliciguat met the primary goal in a key Phase 2 study, driving ROIV shares up 22% in pre-market trading.
Roivant (ROIV) shares surged 22% in pre-market trading on Tuesday and were on track to hit a record high after experimental lung disease drug Mosliciguat met the primary goal in a key Phase 2 study. If the gains hold after the opening bell, ROIV shares would post their biggest single-day advance in more than 2 years.